Fernando Pagan
机构: Georgetown University Hospital
每年引用次数
引用次数
引用: 2,215
H-指数: 22
I10-指数 : 29
出版物: 131
Evaluation of essential tremor with multi-voxel magnetic resonance spectroscopy
F. L. Pagan , J. A. Butman , J. M. Dambrosia , M. Hallett
Neurology 60 ( 8) 1344 -1347
105
2003
Effects of medical comorbidities on Parkinson Disease patients’ quality of life (P6.056)
Fernando Pagan , Tracy Fulton
Neurology 84
2015
Efficacy of apomorphine subcutaneous injections for the management of morning akinesia in Parkinson’s Disease (P1.189)
Mark Lew , Stuart Isaacson , Fernando Pagan , William Ondo
Neurology 84
2015
XCiDaBLE: An Observational, Prospective Trial Evaluating Xeomin (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States - Final Results from the Cervical Dystonia Cohort (P3.009)
Fabio Danisi , Kapil Sethi , Hubert Fernandez , Amit Verma
Neurology 84
2015
Apomorphine Improves Morning Akinesia in Parkinson’s Disease: Interim Analysis of the AM-IMPAKT Trial (P7.072)
Stuart Isaacson , Fernando Pagan , William Ondo
Neurology 82
2014
Overlooking the Skin: Uncovering Comorbid Dermatologic Conditions in Parkinson’s Disease (P6.048)
Ramsey Falconer , Ellen Valadez , Reversa Mills , Kimberly O'Neill
Neurology 84
2015
Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia
Hubert H Fernandez , Fernando Pagan , Fabio Danisi , David Greeley
Tremor and other hyperkinetic movements (New York, N.Y.) 3 ( 3) 03
14
2013
RECOGNISE: Rasagiline Effects on Cognition in Parkinson’s Patients with Mild Cognitive Impairment (P2.343)
Reversa Mills , Fernando Pagan , Jill Farmer , Ishita Gambhir
Neurology 86
2016
Nilotinib Significantly Alters CSF Biomarkers and Increases Endogenous Dopamine in Open-Label Phase I Clinical Trial in Parkinsons Disease with Dementia and Lewy Body Dementia (I1.009)
Michaeline Hebron , Ellen Valadez , Reversa Mills , Fernando Pagan
Neurology 86
2016
Safety and Efficacy of Incobotulinum toxin A for the Treatment of Blepharospasm in Botulinum Toxin-Naive Subjects (P5.041)
Fernando Pagan , Kati Sternberg , Andrzej Dekundy , Dimos Dimitrios Mitsikostas
Neurology 90
2018
Long-term Efficacy and Safety of IncobotulinumtoxinA Treatment for Sialorrhea (S4.007)
Andrew Blitzer , Andrew Blitzer , Andrzej Bogucki , Fernando Pagan
Neurology 92
2019
Long-term Safety and Efficacy of IncobotulinumtoxinA for the Treatment of Blepharospasm in Botulinum Toxin-naïve Subjects: Results of a Phase III Study (S28.005)
Fernando Pagan , Kati Sternberg , Andrzej Dekundy , Dimos Dimitrios Mitsikostas
Neurology 92
2019
Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease
Stuart Isaacson , Mark Lew , William Ondo , Jean Hubble
Movement Disorders Clinical Practice 4 ( 1) 78 -83
23
2017
The Emerging Role of Pimavanserin in the Management of Parkinson’s Disease Psychosis
Neal Hermanowicz , Gustavo Alva , Fernando Pagan , Alberto J. Espay
Journal of managed care & specialty pharmacy 23
1
2017
Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.
Kelly E. Lyons , Rajesh Pahwa , Neal Hermanowicz , Thomas Davis
Expert Review of Clinical Pharmacology 12 ( 7) 681 -691
2
2019
Targeting neurons in the gastrointestinal tract to treat Parkinson's disease
Robert A Hauser , Dean Sutherland , Juan A Madrid , Maria Angeles Rol
Clinical Parkinsonism & Related Disorders 1 2 -7
21
2019
Protection from oxidation enhances the survival of cultured mesencephalic neurons
Carol A. Colton , Fernando Pagan , Julie Snell , Joel S. Colton
Experimental Neurology 132 ( 1) 54 -61
63
1995
Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
Daniel Weintraub , Robert A. Hauser , Jordan J. Elm , Fernando Pagan
Movement Disorders 31 ( 5) 709 -714
28
2016
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.
Wolfgang H. Jost , Andrzej Friedman , Olaf Michel , Christian Oehlwein
Neurology 92 ( 17)
28
2019
O5-03-04: THE LEWY BODY DEMENTIA ASSOCIATION RESEARCH CENTERS OF EXCELLENCE PROGRAM: TOWARD OPTIMIZING CLINICAL CARE AND CLINICAL TRIAL INFRASTRUCTURE
Bradley F. Boeve , Melissa Armstrong , James E. Galvin , Jennifer Goldman
Alzheimers & Dementia 14
2018